Related Experiment Videos
TNK-tPA for acute myocardial infarction: the clinical experience
1Department of Cardiology, University of Leuven, Belgium.
Insights
New thrombolytic therapy, TNK-tPA, shows promise for acute myocardial infarction. Clinical trials suggest improved reperfusion and reduced reocclusion rates compared to current treatments.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thrombolytic therapy is crucial for acute transmural myocardial infarction.
- Current fibrinolytic agents have limitations, including suboptimal reperfusion (40-50%) and reocclusion (10-20%).
Purpose of the Study:
- To summarize clinical trial results of TNK-tPA for acute myocardial infarction.
- To evaluate TNK-tPA as an improved thrombolytic agent.
Main Methods:
- Review of clinical trials involving TNK-tPA.
- Assessment of TNK-tPA's pharmacokinetic and pharmacodynamic properties.
Main Results:
- TNK-tPA demonstrates a longer plasma half-life.
- TNK-tPA exhibits enhanced fibrin-specificity and increased resistance to plasminogen activator inhibitor-1.
- Clinical trials evaluated TNK-tPA's efficacy in acute myocardial infarction.
Conclusions:
- TNK-tPA represents a potential advancement in thrombolytic therapy.
- Further research and clinical application of TNK-tPA are warranted for acute myocardial infarction treatment.
Abstract:
Thrombolytic therapy has become the mainstay of treatment for acute transmural myocardial infarction. Present fibrinolytic regimens have a number of shortcomings, including the failure to induce early and sustained reperfusion in as many as 40-50% of the patients, and to prevent reocclusion in another 10-20% of the patients. The efforts for improving thrombolysis are focused on the development of new agents (fibrinolytics, anticoagulants, and antiplatelet agents). TNK-tPA is a triple combination mutant of wild-type tissue plasminogen activator that exhibits a longer plasma half-life, an enhanced fibrin-specificity, and an increased resistance to the plasminogen activator inhibitor-1. This paper summarizes the results of clinical trials with TNK-tPA in acute myocardial infarction.